Form 4: Hims & Hers CFO Executes Pre-Planned Stock Transactions

Hims & Hers Health, Inc. CFO Oluyemi Okupe executed a Rule 10b5-1 trading plan, involving the vesting of Restricted Stock Units, exercise of stock options, and subsequent sale of Class A Common Stock.

Summary

• Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc., engaged in multiple transactions involving the company's Class A Common Stock on September 15, 2025.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025.
• Okupe acquired 105,199 shares of Class A Common Stock through the vesting and settlement of Restricted Stock Units (RSUs).
• An additional 110,000 shares of Class A Common Stock were acquired through the exercise of stock options at a price of $5.01 per share.
• To cover tax withholding obligations related to RSU vesting, 58,021 shares of Class A Common Stock were disposed of at $53.96 per share.
• Okupe sold a total of 145,000 shares of Class A Common Stock in two separate transactions.
• The first sale involved 117,792 shares at an average weighted price of $55.2503, with prices ranging from $54.725 to $55.720.
• The second sale involved 27,208 shares at an average weighted price of $55.7936, with prices ranging from $55.725 to $55.875.
• Following these transactions, Okupe directly beneficially owns 128,984 shares of Class A Common Stock and indirectly owns 7,853 shares through a trust.
• Remaining derivative securities include 605,434 Restricted Stock Units and 239,784 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are significant sales of shares, these are balanced by the exercise of options and vesting of RSUs, indicating the realization of compensation. The execution under a Rule 10b5-1 plan mitigates any negative interpretation of insider selling, suggesting planned financial management rather than a reaction to negative company prospects.

Positives

• Vesting of a significant number of Restricted Stock Units (105,199 shares) indicates continued equity compensation for the CFO.
• Exercise of stock options at a low price ($5.01) compared to the market sale price (over $55) demonstrates a substantial unrealized gain being realized.
• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned activity and reducing concerns about opportunistic insider selling.

Negatives

• The CFO sold a substantial number of shares (145,000 shares) in the open market, which could be perceived as a reduction in direct exposure to the company's stock.
• A significant portion of acquired shares (58,021 shares) was withheld to cover tax obligations, reducing the net shares received from RSU vesting.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports on insider trading activities.

Management Comments

• The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025 by the Reporting Person.
• The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Industry Context

This insider transaction report is specific to the individual's equity compensation and personal financial planning and does not provide broader insights into industry trends or competitive landscape for Hims & Hers Health, Inc.

Corporate Governance

Related Party Transactions

• The indirect beneficial ownership of 7,853 Class A Common Stock shares is held by the "Oluyemi Okupe Separate Property Trust dtd 9-1-2021," which is a related party transaction as it involves a trust established by the reporting person.

Stakeholder Impact

• Shareholders: The sale of shares by a CFO, even under a 10b5-1 plan, could be viewed with slight caution, but the pre-planned nature generally reduces negative sentiment. The realization of significant gains from options and RSUs demonstrates the value of equity compensation for executives.

Next Steps

• Future vesting of remaining Restricted Stock Units on Company Quarterly Vesting Dates (March 15, June 15, September 15, December 15) as per their respective schedules.
• Future vesting of remaining stock options in monthly installments following the twelve-month anniversary of the Vesting Commencement Date (January 24, 2022).

Key Dates

Recommendation

This Form 4 filing details routine, pre-planned insider transactions by the CFO, including the exercise of options, vesting of RSUs, and subsequent sales under a Rule 10b5-1 plan. While the sales represent a reduction in direct holdings, the pre-planned nature mitigates concerns about opportunistic selling. The filing does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, as the filing does not present a strong catalyst for either buying or selling the stock based solely on these transactions.

Keywords

Hims & Hers Health, HIMS, Oluyemi Okupe, CFO, Insider Transaction, Form 4, Stock Option Exercise, RSU Vesting, Share Sale, Equity Compensation, Rule 10b5-1 Plan